DermaXon received a Phase 1 STTR Grant funding from the National Institute of Arthritis and Musculoskeletal and Skin Diseases to support preclinical efficacy studies for a novel drug treatment for ichthyosis.
This award titled “Selective Inhibition of CYP26A1 in the Skin for the Treatment of Ichthyosis” provides critical support of a research project which examines the efficacy of DermaXon’s technology platform for the treatment of ichthyosis. This award has the potential to increase to $1.5 million, if the Phase 1 project is successful. The platform combines Cytochromes P450 (CYPs) inhibitors and gene expression profiling to identify more efficient and compliant treatments for skin diseases. DermaXon will compare the effect of approved and experimental drugs with their CYP26 inhibitors to mitigate hyperkeratosis associated with ichthyosis.< Back to News